Recent advances in the field of obesity treatment have presented a novel drug known as ALLUVI Retatrutide. This substance is a {highlyspecific GLP-1 receptor agonist, engineered to stimulate the effects of natural glucagon-like peptide-1. Retatrutide has shown impressive efficacy in clinical trials, exhibiting significant decreases in body weight a